Mr. Hsiao is a biopharma investor specializing in U.S.–China cross-border partnerships, licensing, and NewCo deal structures. He oversees Zhongmei Capital’s investment strategy and decision-making, a US based healthcare fund investing in mainland China. His former positions include strategy and business development roles at Monitor Deloitte, IMS Consulting, and Gilead Sciences.

​

Mr. Hsiao holds an MBA from Columbia Business School, and a BS Chemistry from UC Davis